requires
manufacturers
gain
approval
marketing
generic
drug
interstate
drug
manufacturer
prohibited
making
major
changes
quantitative
formulation
drug
including
active
specifications
provided
approved
manufacturers
also
prohibited
making
unilateral
changes
respondent
prescribed
version
nonsteroidal
drug
shoulder
pharmacist
dispensed
generic
form
sulindac
manufactured
petitioner
soon
developed
acute
case
toxic
epidermal
severely
physical
nearly
time
label
specifically
refer
toxic
epidermal
recommended
changing
labeling
contain
explicit
toxic
epidermal
necrolysis
sued
state
removed
case
federal
jury
found
liable
claim
awarded
found
neither
regulations
distinguished
held
claims
generic
manufacturers
prohibition
changes
generic
drug
arguing
generic
manufacturers
facing
claims
comply
federal
state
law
simply
choosing
make
drug
claims
turn
adequacy
warnings
federal
law
state
laws
conflict
federal
law
Even
absence
express
state
law
may
impliedly
private
party
comply
state
federal
impossible
comply
duty
alter
label
composition
duty
either
strengthen
warnings
label
change
cause
action
imposes
affirmative
duties
including
design
products
reasonably
safely
uses
assess
whether
design
dangerous
employs
asks
whether
magnitude
outweighs
repeatedly
identified
three
factors
germane
usefulness
desirability
product
public
whether
risk
danger
reduced
without
significantly
affecting
either
effectiveness
manufacturing
presence
efficacy
warning
avoid
unreasonable
risk
harm
hidden
dangers
foreseeable
Increasing
reducing
require
redesigning
factors
direct
results
chemical
design
active
redesign
possible
two
requires
generic
drug
active
route
dosage
labeling
drug
simple
drug
chemically
incapable
redesign
ameliorate
profile
strengthening
law
ultimately
required
change
makes
clear
federal
law
prevents
generic
drug
manufacturers
changing
See
prohibited
taking
remedial
action
required
avoid
liability
federal
law
forbids
action
required
state
state
law
impossible
comply
state
federal
cause
action
respect
drugs
sold
interstate
escape
impossibility
complying
duties
choosing
stop
selling
incompatible
presumed
actor
seeking
satisfy
obligations
required
cease
acting
delivered
opinion
filed
dissenting
filed
dissenting
opinion
subject
formal
revision
publication
preliminary
print
requested
notify
typographical
formal
order
corrections
may
made
preliminary
print
goes
writ
certiorari
appeals
first
circuit
delivered
opinion
must
decide
whether
federal
law
claim
respondent
recovered
damages
petitioner
manufacturer
generic
nonsteroidal
drug
law
imposes
duty
manufacturers
ensure
drugs
market
unreasonably
safety
evaluated
reference
chemical
properties
adequacy
unable
change
composition
matter
federal
law
basic
cause
action
effectively
required
change
labeling
provide
stronger
recognized
two
Terms
ago
federal
law
prohibits
generic
drug
manufacturers
independently
changing
state
law
imposed
duty
comply
federal
state
laws
require
private
party
violate
federal
law
simply
pulled
sulindac
market
order
comply
state
federal
adopting
rationale
render
impossibility
dead
letter
work
revolution
case
hold
claims
turn
adequacy
warnings
federal
law
reverse
decision
Appeals
drug
manufacturers
must
gain
approval
marketing
drug
interstate
case
new
approval
secured
submitting
application
compilation
materials
must
include
reports
clinical
relevant
nonclinical
data
information
relevant
evaluation
safety
effectiveness
drug
product
obtained
otherwise
received
applicant
must
also
include
labeling
proposed
used
discussion
benefits
exceed
risks
conditions
stated
may
approve
determines
drug
question
conditions
use
suggested
proposed
labeling
order
consider
drug
therapeutic
benefits
must
outweigh
risk
process
submitting
NDA
onerous
typical
spans
thousands
pages
based
clinical
trials
conducted
several
order
provide
swifter
route
approval
generic
passed
popularly
known
generic
drug
may
approved
without
level
clinical
testing
required
approval
new
provided
generic
drug
identical
drug
several
key
proposed
generic
drug
must
chemically
equivalent
approved
must
proposed
generic
must
approved
must
extent
generic
drug
manufacturer
must
show
labeling
proposed
new
drug
labeling
approved
approved
generic
manufacturer
prohibited
making
major
changes
quantitative
formulation
drug
including
active
specifications
provided
approved
manufacturers
also
prohibited
making
unilateral
changes
generic
drug
may
withdrawn
generic
label
longer
consistent
approved
nonsteroidal
pain
reliever
called
brand
name
patent
approved
several
generic
including
one
manufactured
small
number
sulindac
popular
serious
side
effect
causing
two
hypersensitivity
skin
reactions
characterized
necrosis
skin
mucous
toxic
epidermal
less
severe
respondent
prescribed
shoulder
pharmacist
dispensed
generic
form
manufactured
petitioner
soon
developed
acute
case
toxic
epidermal
results
percent
surface
body
burned
turned
open
spent
months
medically
induced
underwent
eye
severely
number
physical
nearly
time
respondent
prescribed
label
specifically
refer
toxic
epidermal
warn
drug
cause
skin
quotation
marks
toxic
epidermal
necrolysis
listed
potential
adverse
reactions
package
respondent
already
suffering
toxic
epidermal
completed
review
risks
including
risk
toxic
epidermal
approved
online
visited
available
case
result
recommended
changes
labeling
including
explicitly
warn
toxic
epidermal
sued
state
removed
case
federal
initially
asserted
dismissed
claim
based
read
box
label
trial
jury
found
liable
awarded
respondent
million
found
neither
regulations
distinguished
held
claims
generic
manufacturers
prohibition
changes
generic
drug
arguing
generic
manufacturers
facing
claims
simply
make
drug
comply
federal
state
granted
provides
laws
treaties
Thing
long
settled
state
laws
conflict
federal
law
also
doctrine
state
however
clearly
within
acknowledged
interferes
contrary
federal
must
quotation
marks
Even
absence
express
found
state
law
impliedly
private
party
comply
state
federal
also
holding
federal
exclusion
state
law
inescapable
requires
inquiry
congressional
design
compliance
federal
state
regulations
physical
impossibility
one
engaged
interstate
instant
impossible
comply
duty
strengthen
warnings
label
duty
alter
state
law
begin
identifying
duties
state
initial
respondent
wrong
asserting
purpose
designdefect
cause
action
cause
action
imposes
affirmative
duties
correct
adopted
doctrine
strict
liability
tort
set
forth
tort
sells
product
defective
condition
unreasonably
dangerous
user
consumer
property
subject
liability
physical
harm
thereby
even
though
exercised
possible
care
preparation
sale
argument
conflates
call
regime
liability
depend
still
signals
breach
call
regime
liability
reflect
breach
duties
merely
serves
spread
adopted
consistently
held
product
design
product
reasonably
safely
uses
also
manufacturer
general
duty
design
product
reasonably
safely
uses
quotation
marks
duty
warn
part
general
duty
manufacture
sell
products
reasonably
safe
foreseeable
limit
application
strict
tort
liability
jurisdiction
continuing
emphasize
liability
without
negligence
liability
without
term
interpreted
broadly
impose
absolute
liability
manufacturers
make
insurers
respondent
incorrect
arguing
system
substantive
duties
tort
law
imposes
duty
manufacturers
Determining
content
duty
requires
somewhat
discussed
greater
requires
manufacturers
ensure
products
sell
recognized
duty
satisfied
either
changing
design
changing
option
changing
law
ultimately
required
change
argues
even
law
impose
duty
drug
duty
encompass
either
change
duty
change
emphasis
argument
imposes
liability
design
product
created
defective
condition
unreasonably
dangerous
determine
whether
product
employs
product
defective
designed
magnitude
danger
outweighs
utility
quotation
marks
approach
requires
balancing
process
involving
evaluation
many
conflicting
quotation
marks
see
also
set
factors
considered
ultimately
open
repeatedly
identified
three
factors
germane
usefulness
desirability
product
public
whether
risk
danger
reduced
without
significantly
affecting
either
effectiveness
manufacturing
presence
efficacy
warning
avoid
unreasonable
risk
harm
hidden
dangers
foreseeable
see
also
drug
either
increasing
product
reducing
require
redesigning
usefulness
risk
danger
direct
results
chemical
design
active
ingredient
means
component
intended
furnish
pharmacological
activity
direct
effect
prevention
affect
structure
function
body
present
redesign
possible
two
requires
generic
drug
active
route
dosage
labeling
drug
correct
recognize
legally
make
sulindac
another
change
composition
altered
chemical
new
drug
require
marketed
interstate
See
examples
considers
drug
including
cases
involving
drug
use
substance
composes
whole
simple
drug
chemically
incapable
legally
make
sulindac
another
composition
apparent
alter
drug
impossibility
redesigning
way
ameliorate
escape
strengthen
presence
efficacy
way
warning
unreasonable
risk
harm
hidden
dangers
foreseeable
also
duty
warn
part
general
duty
manufacture
sell
products
reasonably
safe
foreseeable
design
product
makes
warning
necessary
avoid
unreasonable
risk
harm
foreseeable
lack
warning
ineffective
warning
causes
product
defective
unreasonably
cause
action
imposed
duty
strengthen
unsurprising
allegations
label
inadequate
featured
prominently
introduced
evidence
label
sulindac
time
injuries
label
revised
respondent
suffered
opening
statement
informed
jury
evidence
show
unreasonably
dangerous
inadequate
hear
much
evidence
label
inadequate
relation
repeatedly
instructed
jury
evaluate
labeling
determining
whether
sulindac
unreasonably
instruction
jury
find
defect
found
unreasonably
dangerous
warning
present
effective
avoid
unreasonable
instruction
design
defect
exists
warning
present
effective
avoid
unreasonable
clarified
order
opinion
denying
motion
judgment
matter
law
adequacy
labeling
part
jury
instructed
jury
found
risks
outweighed
consider
whether
risks
extent
eliminated
unreasonable
accordance
jury
presented
evidence
relevant
instructed
whether
fulfilled
duty
label
sulindac
adequately
render
drug
holding
jury
determined
breached
duty
imposed
federal
law
far
readily
made
federal
law
prevents
generic
drug
manufacturers
changing
See
drug
interpreted
prevented
Manufacturers
independently
changing
generic
safety
also
labeling
proposed
new
drug
labeling
approved
approved
generic
drug
may
withdrawn
generic
label
longer
consistent
federal
law
prohibited
taking
remedial
action
required
avoid
liability
federal
law
forbids
action
state
law
state
law
impossible
similarly
situated
manufacturers
comply
state
federal
cause
action
respect
drugs
sold
interstate
reasoned
escape
impossibility
complying
duties
make
sulindac
reject
rationale
incompatible
cases
presume
actor
seeking
satisfy
obligations
required
cease
acting
altogether
order
avoid
option
ceasing
act
defeated
claim
impossibility
incoherence
theory
becomes
plain
viewed
lens
previous
every
instance
found
impossibility
duties
easily
avoided
regulated
actor
simply
ceased
obvious
discussed
held
state
claims
impossible
drug
manufacturers
like
comply
duty
label
products
way
rendered
reasonably
safe
duty
change
possible
drug
manufacturers
like
pull
products
market
avoided
liability
state
federal
manufacturers
neither
labeled
products
way
rendered
unsafe
impermissibly
changed
federally
approved
concluding
impossible
Manufacturers
comply
duty
change
label
federal
law
duty
keep
label
undeterred
prospect
complied
state
federal
requirements
simply
leaving
Appeals
decision
found
claims
escaped
based
rationale
relied
defendants
compelled
market
realized
label
insufficient
simply
stopped
selling
advanced
rationale
petition
squarely
determined
comply
state
federal
Adopting
First
rationale
mean
also
vast
cases
found
impossibility
wrongly
prospect
regulated
actor
avoid
liability
state
federal
law
simply
leaving
market
undermine
impossibility
analysis
irrelevant
analysis
dreadful
injuries
products
liabilities
cases
arise
often
engender
passionate
dissent
sympathy
respondent
relieve
us
responsibility
following
dissent
accuses
us
incorrectly
assuming
federal
law
gives
pharmaceutical
companies
right
sell
federally
approved
drug
free
make
discussed
length
see
hold
claims
like
place
duty
manufacturers
render
drug
safer
either
altering
composition
altering
labeling
conflict
federal
laws
prohibit
manufacturers
unilaterally
altering
drug
composition
dissent
quite
correct
federal
law
establishes
drug
prevent
taking
certain
remedial
state
law
imposes
duty
take
remedial
conflicts
federal
making
private
party
comply
state
federal
dissent
seems
acknowledge
point
concedes
federal
law
requires
particular
product
label
include
complete
list
ingredients
state
law
specifically
forbids
labeling
little
question
state
law
dissent
see
law
requires
specific
label
state
law
forbids
use
dissent
responds
law
creates
alter
label
impose
actual
contours
argument
difficult
Perhaps
dissent
drawing
distinction
statutory
distinction
common
law
statutory
law
irrelevant
argument
violating
surely
violating
statutory
party
contravenes
true
certain
duties
give
manufacturer
choice
exiting
market
continuing
sell
knowing
may
pay
compensation
consumers
injured
statutory
precisely
require
manufacturer
choose
leaving
market
accepting
consequences
actions
form
fine
generally
liability
dissent
agrees
involved
conflicted
federal
see
controls
instant
dissent
reduced
fighting
rearguard
action
reasoning
despite
ostensibly
swearing
fealty
suggest
contrary
simply
dissent
correct
Bates
held
claim
claim
question
labeling
fell
outside
class
claims
covered
express
provision
issue
contrary
impression
one
might
draw
actually
blessed
lower
determination
claim
imposed
correctly
hold
term
reaches
beyond
positive
statutes
embrace
dissent
offers
compelling
reason
case
similarly
viewed
precisely
specific
requirement
state
claim
imposes
Bates
makes
proper
inquiry
calls
examination
elements
duty
call
speculation
whether
jury
verdict
prompt
take
particular
tried
make
duty
ensure
products
imposed
cause
involves
duty
make
one
several
cases
fact
alter
design
increase
decrease
duty
render
product
boils
duty
ensure
presence
efficacy
warning
avoid
unreasonable
risk
harm
hidden
dangers
foreseeable
duty
redesign
label
part
duty
merely
action
might
prompted
take
adverse
jury
verdict
dissent
laments
ignored
explicit
efforts
preserve
state
welcome
resolution
difficult
questions
arise
prescription
drug
issue
repeatedly
vexed
produced
widely
divergent
recent
dissent
treatment
prescription
drugs
includes
neither
express
clause
vaccine
express
clause
drug
absence
sort
expression
congressional
left
divine
duties
statute
federal
law
forbids
Mutual
take
actions
required
state
tort
law
evinces
intent
case
arises
tragic
combination
factors
combined
produce
rare
devastating
injuries
respondent
decision
approve
sale
sulindac
warnings
accompanied
drug
time
decision
physician
prescribe
sulindac
despite
known
decision
regulate
manufacture
sale
generic
drugs
way
reduces
cost
patients
leaves
generic
drug
manufacturers
incapable
modifying
either
compositions
situation
tragic
evokes
deep
straightforward
application
law
requires
judgment
dissenting
writ
certiorari
appeals
first
circuit
literally
impossible
company
like
petitioner
comply
conflicting
state
federal
company
comply
either
business
relevant
paying
state
say
failing
comply
tort
conflicting
state
law
requires
company
withdraw
pay
sizable
damages
remedy
order
avoid
conflict
state
federal
law
may
nonetheless
obstacle
federal
case
relevant
state
law
reasons
set
forth
concurring
part
concurring
deciding
whether
conflict
pay
particular
attention
views
relevant
statute
contains
clear
courts
may
infer
administrative
agency
degree
leeway
determine
extent
governing
administrative
actions
See
Resources
also
responsible
administering
relevant
federal
question
may
call
considerable
one
might
infer
medically
valuable
less
likely
intended
permit
drive
agency
develop
informed
position
question
providing
interested
parties
opportunity
present
translate
understandings
particular
intentions
accompanying
various
rules
communicate
intentions
statements
interpretive
responses
give
special
weight
one
far
briefing
developing
held
hearings
matter
solicited
views
public
another
set
forth
positions
briefs
filed
similar
agency
work
litigating
positions
wholly
unsupported
administrative
entitled
less
ordinary
set
forth
conflicting
views
general
matter
different
briefs
filed
different
previously
found
argued
new
position
entitled
defer
argument
finding
views
vary
time
accorded
less
Without
giving
views
special
conclude
impossible
petitioner
comply
state
federal
regulatory
schemes
federal
regulatory
scheme
state
common
law
potentially
requiring
petitioner
pay
damages
leave
two
former
tell
long
believed
state
tort
litigation
regulatory
enforcement
also
keeping
decision
tort
appears
traditionally
regarded
state
law
complementary
form
drug
unlike
federal
statute
issue
statute
us
contains
general
clause
show
thought
suits
posed
obstacle
found
convincing
reason
believe
removing
particular
drug
requiring
damage
payments
harmful
seriously
undercut
purposes
federal
statutory
similarly
situated
defendants
cases
remain
free
argue
respect
damage
payments
market
demonstrate
type
conflict
particular
might
create
true
incompatibility
state
federal
regulatory
respectfully
dissenting
writ
certiorari
appeals
first
circuit
expanded
scope
impossibility
immunize
generic
drug
manufacturers
unnecessarily
unwisely
extends
holding
Mensing
law
governing
respect
generic
takes
step
concluding
petitioner
held
liable
claim
even
though
clearly
rejected
claim
instead
allowed
liability
distinct
greater
appears
justify
revision
respondent
claim
undefended
assumption
federal
law
gives
pharmaceutical
companies
right
sell
federally
approved
drug
free
derives
proposition
federal
law
order
protect
prohibits
manufacturers
distributing
new
drugs
commerce
without
federal
regulatory
specifically
disavows
intent
displace
state
law
absent
direct
positive
grievously
injured
drug
jury
found
unreasonably
jury
relied
evidence
drug
posed
higher
normal
risk
causing
serious
skin
reaction
produced
horrific
carried
possessed
apparent
offsetting
benefits
compared
similar
pain
like
See
laments
responsibility
fact
deprived
remedy
injuries
rests
established
principles
properly
applied
law
correctly
federal
law
pose
barrier
begin
cornerstones
control
case
conspicuously
absent
majority
purpose
ultimate
every
start
historic
police
powers
superseded
unless
clear
manifest
purpose
particular
force
case
legislated
field
traditionally
occupied
applied
principles
held
state
claim
drug
manufacturer
federal
Tracing
history
federal
drug
regulation
major
explained
federal
drug
law
state
liability
long
understood
operate
tandem
promote
consumer
basic
majority
opinion
essential
understanding
prohibits
interstate
commerce
new
without
prior
approval
generic
drug
manufacturers
required
make
different
showings
receive
agency
approval
premarketing
review
either
permission
market
drug
never
regarded
final
stamp
approval
greater
information
retain
ultimate
responsibility
safety
products
addition
ongoing
obligations
monitor
risks
report
adverse
drug
responses
see
manufacturers
may
sell
drug
used
dosage
manner
called
see
misbranding
prohibition
may
apply
drug
previously
approved
sale
significant
new
scientific
evidence
demonstrates
drug
federal
state
common
law
plays
important
role
federal
drug
law
area
initially
intended
protection
consumers
already
provided
state
regulation
care
preserve
state
amendments
established
premarketing
review
modern
adopted
saving
clause
providing
amendments
construed
invalidate
provision
state
law
absent
direct
positive
years
suits
unabated
enacted
provision
prescription
drugs
even
enacted
provisions
respect
products
regulated
preservation
role
state
law
remedies
reflects
realistic
understanding
limitations
ex
ante
federal
review
even
rigorous
preapproval
clinical
testing
drugs
incapable
detecting
adverse
effects
occur
long
latency
affect
subpopulations
included
adequately
represented
Preempt
see
Protecting
limitations
system
premarket
clinical
tasked
monitoring
thousands
drugs
market
considering
new
drug
faces
significant
resource
constraints
limit
ability
protect
public
dangerous
See
suits
help
fill
gaps
federal
regulation
identify
previously
unknown
drug
Perhaps
state
common
law
provides
injured
consumers
like
seek
redress
available
federal
administrative
legislative
claims
perform
important
role
compensating
accident
always
consistent
repeatedly
cautioned
reading
federal
statutes
means
judicial
recourse
provide
federal
see
legislative
history
suggests
chose
create
federal
cause
action
damages
precisely
believed
state
tort
law
allow
injured
consumers
obtain
light
face
uphill
climb
show
federal
law
claim
generic
drug
manufacturer
defective
majority
nevertheless
accepts
argument
federal
state
law
physical
see
state
law
properly
clear
claim
impose
legal
obligation
violate
federal
law
demanding
requires
defendant
show
federal
state
legal
logic
underlying
true
impossibility
state
federal
law
impose
irreconcilable
affirmative
detailed
congressional
necessary
inference
intended
federal
law
displace
conflicting
state
requirement
federal
law
requires
particular
product
label
include
complete
list
ingredients
state
law
specifically
forbids
labeling
little
question
state
law
key
inquiry
impossibility
identify
whether
state
federal
law
impose
directly
conflicting
affirmative
legal
obligations
state
law
act
unlawful
federal
exist
laws
one
sovereign
permit
activity
laws
sovereign
restricts
even
modify
previous
federal
law
permitted
labeling
practice
state
law
irreconcilable
manufacturer
comply
stringent
impossibility
exist
one
laws
merely
create
incentive
take
action
sovereign
authorized
possible
comply
types
Courts
may
find
state
laws
incentivize
federal
law
discourages
forbid
federal
law
authorizes
reasons
apart
state
laws
may
fall
within
scope
express
pose
obstacle
federal
purposes
intrude
field
intended
federal
law
occupy
absent
direct
conflict
two
mutually
incompatible
legal
impossibility
courts
may
automatically
assume
intended
state
law
give
careful
inquiry
congressional
intent
called
inquiry
informed
presumption
keeping
strict
standard
cases
actually
find
basis
found
impossibility
generic
drug
manufacturer
strengthen
product
label
come
line
duty
warn
without
exercise
judgment
nothing
dictates
finding
impossibility
assess
whether
physically
impossible
comply
federal
state
necessary
identify
precision
relevant
legal
obligations
imposed
cause
majority
insists
required
law
strengthen
warning
taking
majority
effectively
claim
de
facto
majority
relies
hold
jury
found
liable
failing
fulfill
duty
label
sulindac
forbids
generic
drug
manufacturer
independently
alter
safety
see
assertion
held
liable
case
violating
legal
obligation
change
label
inconsistent
state
law
addition
making
argument
embraced
contends
law
effectively
required
change
chemical
composition
claims
physically
impossible
comply
duty
consistent
federal
law
drug
manufacturers
may
change
chemical
composition
products
create
new
drugs
without
submitting
new
drug
application
law
impose
legal
obligation
change
also
mandate
Mutual
change
blackletter
products
liability
law
recognizes
strict
liability
three
different
types
product
manufacturing
design
warning
granted
summary
judgment
cause
action
remains
issue
product
defective
design
law
unreasonable
dangers
determine
whether
product
unreasonably
jury
asked
make
assessment
considering
nonexhaustive
list
specifically
rejected
advocated
plaintiff
must
present
evidence
reasonable
alternative
design
show
design
proof
alternative
design
relevant
design
defect
controlling
factor
essential
jurisdictions
declined
apply
liability
prescription
common
many
subject
prescriptions
drugs
distinct
form
strict
products
see
also
cases
manufacturers
affirmative
defense
comment
exempts
unsafe
strict
liability
product
properly
manufactured
explained
lower
courts
see
takes
approach
comment
defendant
seeking
invoke
defense
must
first
show
product
highly
useful
imposed
product
avoided
feasible
alternative
factor
assessment
liability
case
abandoned
comment
defense
claim
applied
subjects
manufacturer
unreasonably
dangerous
product
require
manufacturer
take
specific
action
forbidden
federal
contrary
see
law
require
Mutual
change
warning
warning
label
one
factor
nonexclusive
list
evaluating
whether
drug
unreasonably
see
adequate
label
therefore
neither
necessary
sufficient
avoiding
law
imposed
duty
change
chemical
held
proof
alternative
design
element
see
majority
sulindac
realistically
capable
redesigned
anyway
claim
creates
incentive
drug
manufacturers
make
changes
including
try
avoid
respondent
overstates
case
somewhat
suggests
law
purely
typically
true
mandates
compensation
serves
compensatory
regulatory
exposure
regulatory
flow
equivalent
legal
mandate
regulated
party
take
refrain
specific
difference
significant
mandate
leaves
choice
party
wishes
comply
whereas
incentive
may
influence
cases
reflect
rejected
argument
claims
brought
pesticide
manufacturer
likely
manufacturer
change
product
label
run
afoul
express
provision
forbidding
state
labeling
different
addition
federal
rule
law
must
jury
merely
motivates
optional
rise
fact
imposing
strict
liability
injuries
caused
defective
drug
design
might
make
drug
manufacturer
want
change
label
design
mean
manufacturer
actually
required
state
law
take
either
absent
legal
impossibility
argument
get
state
requirement
physically
impossible
comply
also
following
federal
case
therefore
unlike
applicable
state
tort
law
drug
manufacturer
aware
strengthen
requirement
conflicted
federal
law
preventing
manufacturer
law
require
anything
compensate
consumers
injured
unreasonably
dangerous
trial
record
case
confirms
held
liable
label
sulindac
filed
suit
raised
distinct
claims
based
design
defect
failure
see
Pursuing
claims
consistent
recognition
defect
failure
warn
claims
granted
summary
judgment
repeatedly
explained
alleged
failure
warn
provide
basis
majority
notes
admitted
evidence
regarding
label
remained
relevant
limited
purpose
combination
whether
design
defective
product
unreasonably
instructions
jury
adhered
limited
first
told
jury
determine
whether
sulindac
unreasonably
dangerous
weighing
danger
instructed
jury
determined
sulindac
unreasonably
dangerous
without
reference
warning
consider
presence
efficacy
label
evaluate
whether
product
unreasonably
dangerous
hold
jury
required
find
sulindac
unreasonably
dangerous
despite
also
explained
jury
claim
addressed
whether
design
included
failure
change
relevant
distinction
drawn
permissible
impermissible
uses
evidence
regarding
label
faithful
law
recognizes
effectiveness
warning
label
one
relevant
factor
determining
whether
design
unreasonably
claims
made
held
liable
distinction
draws
claims
well
clear
repeated
statements
trial
judge
liability
predicated
breaching
duty
label
sulindac
basis
majority
reach
contrary
Though
majority
insists
appears
rely
principally
implicit
assumption
rights
conferred
federal
premarket
approval
correctly
observing
changing
chemical
composition
create
new
drug
go
approval
majority
reasons
must
duty
change
label
option
avoid
liability
continuing
sell
conclusion
based
false
manufacturer
drug
unreasonably
dangerous
law
multiple
change
design
label
effort
alter
remove
drug
pay
compensation
cost
federal
law
chemical
properties
take
redesign
option
mean
manufacturer
suddenly
legal
obligation
state
law
improve
view
state
law
makes
little
sense
even
strengthened
label
fully
account
company
might
still
faced
liability
defective
strict
liability
attach
even
though
adequate
manufacturer
change
label
make
drug
manufacturer
may
still
choose
exiting
market
continuing
sell
knowing
may
pay
compensation
consumers
injured
may
choice
sovereign
may
impose
protect
citizens
dangerous
drugs
least
ensure
seriously
injured
consumers
receive
may
impose
choice
unless
gives
manufacturers
absolute
right
sell
products
free
state
law
otherwise
obstacle
federal
quotation
marks
majority
rely
obstacle
must
believe
manufacturer
received
premarket
approval
right
keep
drug
market
unless
revokes
also
free
liability
makes
proposition
fundamentally
inconsistent
saving
concurring
simply
incorrect
say
federal
law
presupposes
drug
manufacturers
right
continue
sell
drug
free
liability
Nothing
language
framed
prohibition
distribution
without
see
suggests
law
bars
sale
previously
approved
drugs
new
information
comes
light
demonstrating
drug
see
outside
manufacturers
regularly
take
drugs
market
evidence
emerges
particularly
safer
drugs
provide
therapeutic
benefits
According
formal
authority
withdraw
approval
drug
based
new
adverse
see
far
common
manufacturer
stop
selling
product
voluntarily
advises
manufacturer
drug
unsafe
profile
adequately
addressed
labeling
changes
See
cause
action
provide
impetus
action
permitted
sometimes
encouraged
even
required
federal
majority
derides
suggestion
ability
sulindac
relevant
validity
impossibility
argument
built
mistaken
premise
legally
obligated
law
modify
label
way
federal
law
rejecting
impossibility
render
doctrine
dead
majority
revolution
impossibility
case
inferring
requirement
steps
manufacturer
might
wish
take
avoid
mitigate
exposure
products
made
safe
sale
improved
warning
tweak
made
judgment
drugs
initially
approved
distribution
turn
inherently
unreasonably
dangerous
therefore
sold
unless
manufacturer
willing
compensate
injured
Congressional
intent
cause
action
gleaned
existence
federal
specifications
apply
product
whether
depends
assessing
whether
poses
obstacle
federal
policy
approve
sulindac
Yet
skips
analysis
instead
finds
impossibility
exist
relying
assumption
intended
way
continue
selling
sulindac
without
incurring
distinction
impossibility
obstacle
important
obstacle
abused
courts
apply
overly
broad
conception
relevant
federal
purpose
find
see
concurring
useful
framework
case
like
one
least
lead
ask
right
properly
evaluating
asserted
conflict
lens
obstacle
allow
consider
evidence
whether
intended
make
optimal
safety
determination
set
maximum
safety
standard
case
state
tort
law
undermine
rather
minimal
safety
threshold
case
state
tort
law
supplement
overbroad
impossibility
framework
takes
account
federal
drug
safety
review
actually
Though
majority
gestures
rigorous
nature
review
new
drug
nothing
reasoning
turns
premarketing
review
operates
capacity
engage
postmarketing
taking
approach
majority
replaces
careful
assessment
regulatory
structure
ipse
dixit
pharmaceutical
companies
must
way
continuing
sell
drug
received
effectively
makes
highly
contested
policy
judgment
relationship
review
state
tort
sole
guardian
drug
defending
judgment
without
whether
policy
judgment
majority
never
addresses
obstacle
argue
alternative
cause
action
conflicts
purposes
objectives
supplemented
Though
presents
closer
question
impossibility
argument
majority
reject
obstacle
defense
substantial
contention
claim
frustrates
policy
broader
scheme
vesting
authority
expert
agency
determine
drug
designs
enter
remain
interstate
amicus
brief
filed
generally
supports
question
whether
recognizes
factors
weigh
favor
finding
including
absence
textual
support
idea
approved
drug
must
made
available
particular
ultimately
contends
claims
unless
parallel
misbranding
prohibition
agency
permitting
juries
balance
health
risks
benefits
drug
undermine
determinations
reduce
access
drugs
determined
safe
cases
views
impact
tort
law
federal
objectives
subject
matter
technical
relevant
history
background
complex
American
courts
conclusion
state
law
tension
identifies
effort
justify
complete
claims
prescription
drugs
satisfy
high
threshold
must
met
state
law
conflicting
purposes
federal
quotation
marks
see
core
purpose
protecting
recognition
state
tort
law
generally
complements
safety
practical
limits
ability
monitor
promptly
address
concerns
drug
safety
drug
see
absence
federal
remedy
injured
reject
broad
obstacle
argument
troubling
aspect
decision
expand
scope
traditionally
narrow
impossibility
doctrine
implies
relationship
federal
premarket
review
state
remedies
holding
assumption
manufacturers
must
way
avoid
keeping
particular
products
always
create
automatic
conflict
federal
premarket
review
requirement
liability
premarket
prevents
manufacturers
unilaterally
changing
designs
chemical
drugs
less
generic
creation
automatic
conflict
ultimate
continued
expansion
impossibility
result
frankly
adopted
premarketing
approval
requirement
strengthened
response
serious
episodes
involving
unsafe
Yet
act
creating
requirement
order
also
created
operation
law
shield
drug
manufacturers
avoid
paying
damages
state
laws
also
designed
protect
notwithstanding
effort
disclaim
intent
state
reasoning
granting
broad
immunity
entire
industry
judgment
needed
stringent
expanded
notion
impossibility
threatens
disturb
considerable
amount
state
premarket
approval
process
prescription
drugs
provided
model
regulation
many
paired
premarket
regulatory
review
express
provisions
limit
application
state
claims
defective
product
see
prescription
appears
claims
categorically
displaced
either
efforts
set
boundaries
precisely
largely
serious
consequences
product
laws
play
important
role
discovering
also
providing
manufacturers
remove
dangerous
products
market
see
also
tort
system
encourage
regulatory
vigor
manufacturers
products
require
preapproval
given
de
facto
immunity
public
rely
exclusively
imperfect
federal
agencies
limited
resources
sometimes
limited
legal
authority
recall
approved
consumers
injured
products
manner
addressed
respect
vaccines
particularly
subject
federal
premarket
approval
process
prescription
prior
injuries
left
largely
response
rise
tort
suits
produced
instability
vaccine
enacted
established
compensation
program
funded
excise
tax
vaccines
compensate
individuals
injured
killed
vaccine
side
quid
pro
quo
stated
provision
significant
protections
vaccine
Members
disagreed
scope
tort
protections
intended
history
demonstrates
perfectly
capable
responding
believes
state
tort
law
may
compromise
significant
federal
objectives
scheme
premarket
regulatory
review
products
wants
make
illustrates
important
reason
require
preemption
decisions
made
rather
courts
basis
expanded
implied
ability
tie
decisions
alternative
means
securing
instead
reaching
find
context
never
intended
majority
leaves
consumers
like
bear
enormous
losses
recognizes
case
arises
tragic
doubt
Members
majority
personally
feel
sympathy
solemn
affirmation
merely
discharges
duty
gives
effect
policy
rather
hard
expanding
scope
impossibility
turns
intent
head
arrives
holding
irreconcilable
left
seriously
injured
consumer
without
remedy
despite
explicit
efforts
preserve
state
respectfully
save
another
day
question
whether
true
system
give
rise
impossibility
causes
action
negligence
strict
liability
exist
merely
spread
rather
impose
affirmative
five
Justices
concluded
causes
action
negligence
strict
liability
impose
federal
requirements
specific
medical
adhere
reference
includes
plurality
opinion
said
liability
existence
legal
tort
judgment
therefore
establishes
defendant
violated
liability
turned
adequacy
warnings
large
majority
adopted
comment
recognizes
common
field
products
made
safe
intended
ordinary
comment
properly
accompanied
proper
directions
unreasonably
Restatement
previously
noted
large
number
took
comment
mean
manufacturers
face
strict
liability
side
effects
properly
manufactured
prescription
drugs
accompanied
adequate
Mutual
withdrew
comment
defense
purposes
trial
noted
respondent
trial
injected
broader
question
adequacy
label
trial
argues
comply
state
federal
law
escape
liability
business
relevant
paying
state
say
failing
comply
tort
aside
rare
case
state
federal
law
actually
requires
product
pulled
cases
presume
ability
stop
selling
turn
impossibility
dual
orders
forbade
picking
marketing
avocado
testing
test
excluded
avocado
measuring
less
oil
forecloses
argument
impossibility
defeated
prospect
manufacturer
state
violating
prospect
defeated
impossibility
impossible
Manufacturers
comply
duty
change
label
federal
law
duty
keep
label
hold
otherwise
render
impossibility
address
state
claims
parallel
federal
misbranding
misbranding
statute
requires
pull
even
drug
market
even
dosage
frequency
duration
suggested
labeling
pesticide
labeling
requirement
express
provided
fully
consistent
federal
misbranding
parties
appear
agree
drug
misbranded
federal
law
liability
based
new
scientifically
significant
information
jury
asked
find
whether
new
evidence
concerning
sulindac
made
available
rendered
sulindac
dangerous
misbranded
federal
misbranding
misbranding
provision
applicable
testimony
directly
medical
literature
published
attempts
distinguish
case
arguing
state
law
imposes
affirmative
duty
manufacturer
improve
suspending
sales
comply
merely
offers
indirect
means
avoiding
liability
noncompliance
difference
purely
duty
amend
label
easily
phrased
duty
sell
drug
without
adequate
least
imposes
liability
based
balancing
harms
benefits
light
directly
prohibiting
mere
fact
manufacturer
may
avoid
liability
leaving
market
defeat
claim
failure
adhere
presumption
well
illustrated
fact
majority
calls
provide
greater
clarity
regard
questions
arise
prescription
drug
clear
direction
questions
whole
point
presumption
congressional
ambiguity
cut
favor
preserving
state
requirements
nonprescription
packaging
requirements
included
saving
clause
statutes
addressing
nonprescription
drugs
makes
clear
express
provisions
statutes
affect
state
product
liability
See
Though
majority
rely
comment
find
misleadingly
implies
like
large
majority
applied
comment
categorically
prescription
drugs
exempt
manufacturers
liability
side
effects
properly
manufactured
prescription
drugs
accompanied
majority
also
neglects
mention
courts
applied
comment
categorically
prescription
drug
courts
stated
justification
giving
prescription
drug
manufacturers
blanket
immunity
strict
liability
comment
American
Like
courts
apply
comment
feature
unnecessary
consider
whether
analysis
differ
jurisdiction
required
proof
feasible
alternative
design
element
majority
suggests
account
simply
misses
recognize
duties
may
qualify
least
term
used
express
provisions
federal
determining
precisely
specific
requirement
state
claim
imposes
lower
accepted
basic
argument
majority
advances
claim
pesticide
disguised
claim
failure
success
claim
pesticide
dangerous
crops
soil
certain
pH
level
manufacturer
change
label
avoid
explicitly
rejected
notion
liability
might
lead
manufacturer
make
label
meant
claim
imposed
requirement
labeling
majority
contends
case
different
duty
redesign
label
element
altering
product
label
merely
one
step
manufacturer
might
take
prevent
product
considered
unreasonably
step
law
recognizes
may
ruling
proposed
jury
made
clear
allowed
circumvent
summary
judgment
ruling
using
warning
establish
drug
unreasonably
dangerous
arguing
unreasonably
dangerous
already
ruled
inadequacy
warning
cause
explained
effectively
turn
case
back
rendering
summary
judgment
ruling
later
told
counsel
removed
instruction
jury
instructions
failure
warn
admonished
counsel
arguing
warning
label
adequacy
issue
extent
majority
believes
practice
allowed
adequacy
warning
label
play
greater
role
trial
see
irrelevant
question
even
change
state
law
cause
action
evaluate
specifically
concluded
jury
instructions
appropriate
wanted
caution
concerning
warning
sought
suggestion
option
continuing
sell
paying
compensation
akin
violating
statutory
mandate
suffering
consequence
paying
manufacturer
violated
fact
law
enforced
monetary
sanctions
injunction
change
matter
many
times
majority
insists
manufacturer
sells
drug
whose
design
found
unreasonably
dangerous
based
balance
factors
violated
state
law
requiring
change
manufacturer
may
owe
former
failed
follow
condition
triggers
tax
necessarily
take
certain
majority
properly
leaves
open
question
whether
state
claims
parallel
federal
misbranding
statute
majority
fails
statute
undermines
impossibility
argument
compared
argument
based
obstacle
shows
federal
right
obligation
continue
sell
drug
like
sulindac
previously
statute
demonstrates
sometimes
drug
manufacturer
like
may
federal
duty
sell
drugs
voluntarily
withdrawn
safety
reasons
Archives
drugs
drug
products
withdrawn
market
safety
reasons
Defending
policy
judgment
treats
exclusive
guarantor
drug
safety
easy
task
light
evidence
resource
constraints
gaps
legal
among
limit
ability
safeguard
public
Preempt
see
also
purports
address
calls
references
way
separate
discussion
claim
based
premise
claim
turns
adequacy
note
confronted
case
promulgated
specific
regulations
whether
circumstances
state
liability
interferes
safe
medical
sought
also
least
creates
automatic
conflict
caveat
claims
parallel
federal
duty
manufacturers
withdraw
product
might
medical
